NEXSEN LIMITED (ASX: NXN) — Company Overview, News & Financial Data
NEXSEN LIMITED is an Australian medical technology company focused on developing a suite of rapid point-of-care diagnostics for clinical conditions that traditionally depend on delayed laboratory testing.
NEXSEN LIMITED
NEXSEN LIMITED is an Australian medical technology company focused on developing a suite of rapid point-of-care diagnostics for clinical conditions that traditionally depend on delayed laboratory testing. The company's proprietary technology platform integrates modular lateral flow architecture, ultra-bright nanoparticles, and machine learning for biomarker discovery to enable fast and reliable testing. Its clinical pipeline targets maternal health, renal care, biosecurity, and animal health applications. Key programs include StrepSure for real-time Group B Streptococcus screening in expectant mothers, rapid diagnostic tests for acute kidney injury and chronic kidney disease, biosecurity sensors for pathogen detection, and on-farm bovine mastitis testing.
Snapshot
Operations
Products and/or services of NEXSEN LIMITED
- Group B Streptococcus Diagnostic Sensors: Rapid point-of-care diagnostic tests in development for real-time detection of Group B Streptococcus in expectant mothers. The diagnostic system enables fast testing closer to delivery to guide clinical decisions and reduce neonatal infection risks.
- Chronic Kidney Disease Diagnostics: Early detection and monitoring sensors for renal health, providing rapid point-of-care diagnostics to identify chronic kidney dysfunction. The solution aims to deliver fast results outside central laboratories to support earlier therapeutic intervention and clinical care.
- Acute Kidney Injury Testing: Point-of-care testing solutions designed for intensive care units and emergency departments to enable early detection of acute kidney injury. The rapid diagnostic format supports immediate clinical decision-making during critical care scenarios.
- Bovine Mastitis Veterinary Diagnostics: On-farm rapid diagnostic sensors developed for agricultural applications to detect bovine mastitis in dairy cattle. The portable testing system allows livestock producers to manage herd health, optimize treatment timing, and minimize agricultural financial losses.
- Frontline Biosecurity Sensors: Portable diagnostic systems designed for frontline pathogen detection and biosecurity monitoring. The compact testing format enables rapid pathogen identification in field settings, agricultural operations, and remote environments to support early biosecurity threat containment.
- Diagnostic Platform Technology: Modular lateral flow testing architecture paired with proprietary nanoparticle signal enhancement and machine learning biomarker discovery. The technology platform accelerates product development, simplifies scalable manufacturing, and powers multi-sector rapid point-of-care diagnostic applications.
NEXSEN LIMITED executive team
- Mark Anthony MuzzinFounder, MD, Advisory Board Member & Executive Director
- Richard Mark JarvisChief Financial Officer
- Sanje MahasivamResearch Team Leader & CTO
- Shekhar KumtaExecutive Director
- Vipul BansalChief Innovation Officer & Advisory Board Chair
- Sonny DiduguCompany Secretary
Latest news about NEXSEN LIMITED
Nexsen signs non-binding deal for 50:50 joint venture
AustraliaNexsen delays StrepSure FDA submission by one quarter
AustraliaNexsen secures first strategic hospital partner in Asia
AustraliaNexsen and Universiti Malaya launch food safety hub
AustraliaNexsen secures HK$6M grant for Asian expansion
AustraliaNexsen accelerates global rollout for StrepSure rapid sensor
Australia
Recent announcements
What NEXSEN LIMITED (NXN) has told the market, newest first.
- Notice of AGM and Meeting Materials
- Professor Shekhar Kumta appointed Executive Director
Key financials
Reported results for NEXSEN LIMITED, in AUD.
- Market cap
- 32.3M
- Revenue (TTM)
- 931.6K
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| — | -6.9M | -6.6M |